Lymphoma Recurrence: What Does It Mean?

Hearing about lymphoma recurrence is about the least-welcome news a patient can hear. But what exactly does it mean?

To begin, lymphoma recurrence doesn't mean anything 'exactly', meaning it's not an exacting term with well-defined parameters. In general, a lymphoma recurrence means that they have received treatment and that following treatment there was a period of time during which their cancer was not detected. It further means that their lymphoma has returned. It may have returned in a different region of the body than where it got its start—no matter. It is still a case of lymphoma recurrence.

Generally speaking, in order for one's lymphoma to be considered a lymphoma recurrence, it would need to have been undetectable for at least one year. If it were detectable within a year of receiving treatment, oncologists would classify this as progressive lymphoma.

Naturally, the goal with each patient is to bring about long-term remission and in some cases a cure with first-line therapy, but this is not the reality. Fortunately for many subtypes of lymphoma, second-line therapies exist and have shown to be effective in many instances of lymphoma recurrence.

Photo: Pexels

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap